MedTrace Logo

Denosumab, Teriparatide or Both for the Treatment of Postmenopausal Osteoporosis

NCT00926380 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 94

Last updated 2018-06-29

Study results available
· View outcomes & findings →

Summary

The aim of this study is to determine whether denosumab (an FDA-approved osteoporosis therapy), in combination with teriparatide (an FDA-approved osteoporosis therapy), will increase bone mineral density more than either one alone in postmenopausal osteoporotic women.

Conditions

Interventions

DRUG

denosumab

denosumab: 60 mg SC every 6 months

DRUG

teriparatide

teriparatide: 20 mcg SC QD

Sponsors & Collaborators

  • Amgen

    collaborator INDUSTRY

  • Massachusetts General Hospital

    lead OTHER

Principal Investigators

  • Benjamin Z Leder, MD · Massachusetts General Hospital

  • Robert M Neer, MD · Massachusetts General Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
45 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-06-30
Primary Completion
2016-12-31
Completion
2016-12-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00926380 on ClinicalTrials.gov